Paris-based Jeito Capital has closed its second fund at $1.2 billion (above €1 billion), making it the largest raise ever by a fully independent European biopharma fund. Jeito II will invest in 15 to 20 clinical-stage biopharma companies with average investments of up to €150 million per company.
The women’s health relevance: Jeito has already deployed capital into reproductive medicine, backing ReproNovo in a $65 million round in May 2025. The Swiss-headquartered company is developing RPN-002 (nolasiban), a first-in-disease, first-in-class molecule for adenomyosis and to increase the probability of embryo implantation in women undergoing assisted reproductive technology. The compound is Phase 2 ready.
Adenomyosis – where tissue similar to the uterine lining grows into the muscular wall of the uterus – affects an estimated 20-35% of women and is linked to heavy bleeding, pain, and fertility complications, yet has no approved targeted therapy. A first-in-class approach backed by a fund of this scale signals meaningful capital flowing into an underserved condition.
“The closing of Jeito II at more than one billion euros represents a very significant milestone for our business,” said founder and CEO Dr. Rafaèle Tordjman. “It is also a strong signal for the European Biopharma ecosystem, demonstrating the growing conviction that European companies can drive major therapeutic innovation and significant economic benefits with the appropriate access to financial and strategic resources.”
Jeito’s three exits to date include acquisitions by Merck (MSD) and Biogen totaling up to $4.8 billion in deal value, with an average holding period of 24 months. The fund counts sovereign funds, pharma corporates, pension funds, and family offices among its investor base across Europe, North America, and Asia.
